Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

538
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
538
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

786
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
786
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.7K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.7K
Angina IV: Management01:26

Angina IV: Management

368
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
368
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

465
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
465

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of CETP inhibitors in patients with atherosclerotic cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials.

Journal of cardiovascular pharmacology·2026
Same author

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies.

Progress in cardiovascular diseases·2026
Same author

Low-Density Lipoprotein Cholesterol Goal Attainment in Indian Patients With Coronary Artery Disease: A Nationwide Study.

JACC. Asia·2026
Same author

Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence.

TouchREVIEWS in endocrinology·2026
Same author

Portopulmonary hypertension and serum endothelin-1 levels in patients with liver cirrhosis.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2026
Same author

From Induction to Maintenance? Rethinking GLP-1-Based Obesity Pharmacotherapy in the Era of Oral Agents.

Diabetes, obesity & metabolism·2026

Related Experiment Video

Updated: Mar 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

2025 ESC/EAS Dyslipidemia Guidelines Focused Update: Intensifying Prevention, Risk Stratification, and Therapy.

Akshyaya Pradhan1, Prashant Thandi1, Kunal Mahajan2

  • 1Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India.

The American Journal of Cardiology
|March 5, 2026
PubMed
Summary

The 2025 ESC/EAS lipid guidelines update introduces SCORE2/SCORE2-OP for better atherosclerotic cardiovascular disease (ASCVD) risk assessment. It emphasizes intensified lipid-lowering therapy for higher-risk individuals, improving cardiovascular disease prevention.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.6K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.9K

Related Experiment Videos

Last Updated: Mar 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.6K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.9K

Area of Science:

  • Cardiology
  • Atherosclerosis Research
  • Preventive Medicine

Background:

  • Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD).
  • Previous risk assessment tools require updates to reflect current evidence and therapeutic advancements.
  • The European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) provide guidelines for lipid management.

Purpose of the Study:

  • To present the 2025 Focused Update of the ESC/EAS Guidelines for the management of lipid disorders.
  • To outline advancements in cardiovascular disease (CVD) risk assessment and novel therapeutic strategies.
  • To provide evidence-based recommendations for optimizing lipid management in CVD prevention.

Main Methods:

  • Transition from the SCORE system to the SCORE2 and SCORE2-OP risk models for 10-year ASCVD risk estimation.
  • Inclusion of both fatal and non-fatal cardiovascular events in risk calculations, extending age range to 89.
  • Recalibration of country-specific risk clusters and prioritization of non-HDL cholesterol over total cholesterol.

Main Results:

  • The SCORE2 and SCORE2-OP models offer broader applicability and more precise risk stratification.
  • Emphasis on intensified lipid-lowering therapy for high-risk individuals based on updated clinical trial data.
  • Updated guidelines contrast recommendations with the 2019 standard, detailing new strategies for primary and secondary prevention.

Conclusions:

  • The 2025 ESC/EAS guidelines represent a significant evolution in CVD prevention strategies.
  • Implementation of these guidelines is expected to further reduce ASCVD events.
  • The guidelines serve as a crucial tool for clinicians and researchers in managing lipid disorders and cardiovascular risk.